eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, announces the expansion of its strategic collaboration with the VUB with the signing of an exclusive license for TetraMix® , a new generation of the TriMix® adjuvant technology.
Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy (LMCT) of the VUB.
